COMMUNIQUÉS West-GlobeNewswire

The Canadian Dermatology Association urges Canadians to protect themselves from skin cancer this summer
01/05/2024
OTTAWA, May 01, 2024 (GLOBE NEWSWIRE) -- The Canadian Dermatology Association (CDA) has launched its annual month-long Sun Awareness Campaign. This year is focused on protecting children and adolescents; the campaign [...]
L’Association canadienne de dermatologie incite les Canadiens à se prémunir contre les cancers de la peau cet été
01/05/2024
OTTAWA, 01 mai 2024 (GLOBE NEWSWIRE) -- L’Association canadienne de dermatologie (ACD) lance sa campagne annuelle Prudence au soleil, d’une durée d’un mois. Cette année, l’accent sera mis sur la protection des enfants [...]
Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8
01/05/2024
DUBLIN, Ireland, May 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a [...]
VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting
01/05/2024
Presentations will highlight positive preclinical and Phase 1b data of novel BET inhibitor, VYN201, in nonsegmental vitiligo BRIDGEWATER, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“ [...]
Auron Announces Oral Presentation on Preclinical Data from Proprietary AURIGIN™ Platform at the AI in Biomedicine Keystone Symposia
01/05/2024
NEWTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Auron Therapeutics , a biotechnology company focused on developing next-generation targeted therapies by identifying and inhibiting the oncogenic cell states of cancer, [...]
CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024
01/05/2024
- CX-904 (masked EGFRxCD3 Probody ® T-cell engager) preliminary Phase 1a results to be presented from ongoing dose escalation study - - Management to hold conference call at 5 p.m. EDT / 2 p.m. PDT on May 8 th - SOUTH [...]
Pliant Therapeutics to Participate in Upcoming Investor Events
01/05/2024
SOUTH SAN FRANCISCO, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the [...]
Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza
01/05/2024
BOTHELL, Wash., May 01, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces completion of enrollment of 78 subjects who were infected with influenza A in a randomized [...]
Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the National Kidney Foundation 2024 Spring Clinical Meetings
01/05/2024
WALTHAM, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet [...]
Touro University Nevada College of Osteopathic Medicine Teaches Living Anatomy and Physiology with Vave Health Pocket Ultrasound
01/05/2024
Largest Medical School in Nevada Provides Every Student with Wireless, Portable Ultrasound SAN JOSE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Vave Health, the company on a mission to put ultrasound in every medical [...]
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
01/05/2024
Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT [...]
PharmaTher’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine
01/05/2024
TORONTO, May 01, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, announced today Sairiyo Therapeutics Inc. (“Sairiyo”), a [...]
Avalyn Bolsters Leadership Team with the Appointment of Douglas Carlson as Chief Financial Officer and Chief Business Officer
01/05/2024
Industry veteran Douglas Carlson to steer Avalyn’s finance and business functions as company nears late-stage clinical development for lead programs CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc [...]
AltruBio to Participate in Upcoming May 2024 Medical Conferences
01/05/2024
SAN FRANCISCO, May 01, 2024 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of immunological [...]
Annexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual Meeting
01/05/2024
Additional data from the Phase 2 ARCHER trial demonstrating protection of visual acuity and anatomical structure following ANX007 treatment will be featured as an oral presentation New preclinical data on the pathogenic [...]
BetterLife Advances BETR-001 IND-enabling Studies
01/05/2024
VANCOUVER, British Columbia, May 01, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU ), an emerging biotech company focused on the development and [...]
Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
01/05/2024
SOUTH SAN FRANCISCO, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain [...]
ImmuneSensor Therapeutics Appoints Veteran Biopharma Executive, Thomas W. Dubensky, Jr., Ph.D., as Chief Executive Officer
01/05/2024
Company debuts with pipeline of cGAS-STING pathway inhibitors and agonists DALLAS, May 01, 2024 (GLOBE NEWSWIRE) -- ImmuneSensor Therapeutics, a clinical-stage biotherapeutics company focused on the development of best- [...]
Bionano to Report First Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 8, 2024
01/05/2024
SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, May 8, 2024, at 4:30 p.m. Eastern Time to report [...]

Pages